$0.70-2.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 10, 2026
Just reported
From Metagenomi Therapeutics, Inc.'s results release of November 10, 2026; its quarterly report has since been filed.
Actual
$2.2M
-75% y/y
Guided
—
No guide given
Actual
-$0.56
Guided
—
No guide given
Actual
-$22.2M
Guided
—
| Measure | 3 months toSep 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $2.2M | $8.5M | -74.35% |
| Profit | -$21.1M | -$20.4M | -3.59% |
| Profit per share | -$0.56 | -$0.55 | -1.82% |
| Free Cash Flow | -$19.1M | -$21.3M | +10.62% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Metagenomi Therapeutics, Inc. reported on November 10, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We are thrilled to reach this pivotal milestone with the FDA clearance of our IND for MGX-001, our lead, wholly owned program in hemophilia A,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
MGX-001 is an investigational, one-time genome editing treatment designed to provide life-long protection from bleeding events and joint damage in adults and children with hemophilia A. MGX-001 is designed to site-specifically integrate the FVIII gene in a “safe harbor” location within an intron of the albumin gene, leveraging the strong native albumin promoter to drive endogenous FVIII expression. MGX-001 consists of an adeno-associated virus (AAV) vector that delivers the promoterless FVIII gene cassette as donor DNA, and a lipid nanoparticle (LNP) that delivers mRNA encoding the Company’s proprietary Type V CRISPR nuclease, MG29-1, together with a guide RNA targeting the albumin gene. This represents a departure from prior approved gene therapy for hemophilia A that relied on episomal FVIII expression. In preclinical studies in non-human primates (NHPs), MGX-001 demonstrated FVIII activity in the normal physiologic range, with clear dose dependency across both the AAV and LNP components, and, in an earlier study, durable FVIII activity over approximately 19 months. MGX-001 has also shown no detectable off-target editing in a series of orthogonal assays.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Metagenomi Therapeutics, Inc.’s Item 2.02 8-K filed November 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.